Retatrutide is a novel once-weekly triple agonist for the GLP-1R, GIPR, and GCGR receptors, showing a stronger action on the human GIP receptor, and exerting weaker effects on the GLP-1 and glucagon receptors
In the UK the changes mean the suggested price for a month's supply of the highest dose of the drug will rise from 122 to 330, although the rise for lower doses will be smaller
Most people start noticing subtle changes within a few days to weeks, though the timeline varies depending on your starting health status, lifestyle, and treatment frequency
While some patients experience weight plateaus or adaptive changes, these typically reflect normal metabolic adjustments rather than the body becoming resistant to the medication's core mechanisms
1 in 10 Britons and 1 in 16 Americans have more regular menstrual cycles on GLP-1s